Management of Drug Toxicities in Chronic Myeloid Leukaemia

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 3, 2009, Pages 409-429

  Mauro, Michael J ^a   Deininger, Michael W ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

CML; kinase inhibitors; toxicity

Indexed keywords

ALPHA INTERFERON; ANALGESIC AGENT; ANTACID AGENT; ANTIINFLAMMATORY AGENT; BUSULFAN; CORTICOSTEROID; CYCLOSPORIN A; DASATINIB; DIURETIC AGENT; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; HYDROXYUREA; IMATINIB; LOPERAMIDE; METOPROLOL; NIFEDIPINE; NILOTINIB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARACETAMOL; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; SIMVASTATIN; SPIRONOLACTONE; STEROID; UNINDEXED DRUG; VERAPAMIL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLAST CELL CRISIS; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE PAIN; CALCIUM BLOOD LEVEL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CROSS TOLERANCE; CYTOPENIA; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG MILK LEVEL; DRUG MONITORING; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ERYTHEMA MULTIFORME; FACE EDEMA; FLUID RETENTION; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HAIR DISCOLORATION; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERPIGMENTATION; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOPIGMENTATION; KIDNEY DYSFUNCTION; LEG EDEMA; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; LUNG EDEMA; MAGNESIUM BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PANCREATITIS; PATIENT COMPLIANCE; PERICARDIAL EFFUSION; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHILADELPHIA 1 CHROMOSOME; PLASMA HALF LIFE; PLEURA EFFUSION; PREGNANT WOMAN; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; STEVENS JOHNSON SYNDROME; SUBDURAL HEMATOMA; TERATOGENICITY; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE MANAGEMENT; DRUG MONITORING; DRUG RESISTANCE, NEOPLASM; DRUG TOXICITY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; TREATMENT FAILURE;

EID: 71849116714     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.06.001     Document Type: Review

References (90)

1. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 14 (Apr 5 2001) 1031-1037
2. Peng B., Hayes M., Resta D., et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22 5 (Mar 1 2004) 935-942
3. Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99 6 (Mar 15 2002) 1928-1937
4. Cortes J., Giles F., O'Brien S., et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 102 1 (2003 Jul 1) 83-86
5. Kantarjian H., Talpaz M., O'Brien S., et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103 8 (Apr 15 2004) 2873-2878
6. Cortes J.E., Baccarani M., Guilhot F., et al. First report of the TOPS study: a randomized Phase III trial of 400 mg vs 800 mg imatinib in patients with newly diagnosed, previously untreated CML in chronic phase using molecular endpoints. Haematologica 93 (2008) Abstract 402
7. Larson R.A., Druker B.J., Guilhot F., et al. Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib - an analysis of IRIS study data. ASH Annual Meeting Proceedings. Blood 108 (2006) Abstract 429
8. Larson R.A., Druker B.J., Guilhot F., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111 8 (2008 Apr 15) 4022-4028
9. Picard S., Titier K., Etienne G., et al. Trough plasma imatinib concentrations are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. ASH Annual Meeting Proceedings. Blood 108 (2006) Abstract 2141
10. Forrest D.L., Trainor S., Brinkman R.R., et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 33 2 (2009 Feb) 271-275
11. Mahon F.X., and Molimard M. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia. Leuk Res 33 8 (2009 Aug) 1147-1148 (Epub 2009 Apr 23)
12. Blasdel C., Wang Y., Lagattuta T., et al. Therapeutic drug monitoring of imatinib and impact on clinical decision making. ASH Annual Meeting Proceedings. Blood 108 (2006) Abstract 4820
13. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 24 (2006 Jun 15) 2542-2551
14. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 24 (2006 Jun 15) 2531-2541
15. Hochhaus A., Kantarjian H.M., Baccarani M., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109 6 (2007 Mar 15) 2303-2309
16. Shah N.P., Kantarjian H.M., Kim D.W., et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26 19 (2008 Jul 1) 3204-3212
17. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 23 (Dec 7 2006) 2408-2417
18. Hochhaus A., Druker B., Sawyers C., et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 111 3 (2008 Feb 1) 1039-1043
19. Silver R.T., Cortes J., Waltzman R., et al. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica 94 5 (2009 May) 743-744
20. Kantarjian H.M., Giles F., Gattermann N., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110 10 (2007 Nov 15) 3540-3546
21. le Coutre P., Ottmann O.G., Giles F., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111 4 (2008 Feb 15) 1834-1839
22. Guilhot F., Apperley J., Kim D.W., et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109 10 (2007 May 15) 4143-4150
23. Cortes J., Rousselot P., Kim D.W., et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109 8 (2007 Apr 15) 3207-3213
24. Ottmann O., Dombret H., Martinelli G., et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110 7 (2007 Oct 1) 2309-2315
25. Hughes T.P., Branford S., White D.L., et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 112 10 (2008 Nov 15) 3965-3973
26. Marin D., Marktel S., Bua M., et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia 17 8 (2003 Aug) 1448-1453
27. Jabbour E., Hochhaus A., le Coutre P., et al. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP). ASCO Annual Meeting Proceedings. J Clin Oncol 26 (2008) Abstract 7063
28. Cortes J., O'Brien S., Borthakur G., et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). ASH Annual Meeting Proceedings. Blood 112 (2008) Abstract 182
29. Cortes J., O'Brien S., Jones D., et al. Efficacy of nilotinib (formerly AMN107) in patients (Pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). ASH Annual Meeting Proceedings. Blood 112 (2008) Abstract 446
30. Marin D., Marktel S., Foot N., et al. Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica 88 2 (Feb 2003) 227-229
31. Quintas-Cardama A., Kantarjian H., O'Brien S., et al. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 100 12 (Jun 15 2004) 2592-2597
32. Mauro M.J., Kurilik G., Balleisen S., et al. Myeloid growth factors for neutropenia during imatinib mesylate (STI571) therapy for CML: preliminary evidence of safety and efficacy. Blood 98 (2001) 139a
33. Ault P., Kantarjian H., Welch M.A., et al. Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia. Leuk Res 28 6 (Jun 2004) 613-618
34. Cortes J., O'Brien S., Quintas A., et al. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 100 11 (Jun 1 2004) 2396-2402
35. Quintas-Cardama A., Han X., Kantarjian H., et al. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood (2009) Epub 5/4/09
36. Deininger M.W., O'Brien S.G., Ford J.M., et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21 8 (Apr 15 2003) 1637-1647
37. Hazarika M., Jiang X., Liu Q., et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 14 17 (2008 Sep 1) 5325-5331
38. Brave M., Goodman V., Kaminskas E., et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14 2 (2008 Jan 15) 352-359
39. Quintás-Cardama A., Kantarjian H., O'brien S., et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25 25 (2007 Sep 1) 3908-3914
40. de Lavallade H., Punnialingam S., Milojkovic D., et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 141 5 (2008 May) 745-747
41. Mustjoki S., Ekblom M., Arstila TP., et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23 8 (2009 Mar 19) 1398-1405
42. Ramar K., Potti A., and Mehdi S.A. Uncommon syndromes and treatment manifestations of malignancy: case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia. J Clin Oncol 21 1 (Jan 1 2003) 172-173
43. Esmaeli B., Prieto V.G., Butler C.E., et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 95 4 (Aug 15 2002) 881-887
44. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 5 3 (Mar 2006) 228-231
45. Etienne G., Cony-Makhoul P., and Mahon F.X. Imatinib mesylate and gray hair. N Engl J Med 347 6 (2002 Aug 8) 446
46. Tsao A.S., Kantarjian H., Cortes J., et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer 98 11 (2003 Dec 1) 2483-2487
47. Marin D., Marktel S., Bua M., et al. The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations. Haematologica 87 9 (Sep 2002) 979-988
48. Berman E., Nicolaides M., Maki R.G., et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354 (2006) 2006-2013
49. Osorio S., Noblejas A.G., Duran A., et al. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukaemia in late chronic phase, and this effects is associated with response. Am J Hematol 82 (2007) 394-395
50. Grey A., O'Sullivan S., Reid J.R., et al. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 355 (2006) 2494-2495
51. Fitter S., Dewar A.L., and Kostakis P. Long-term imatinib therapy promotes bone formation in CML patients. Blood 111 (2008) 2538-2547
52. Jonsson S., Olsson B., Ohlsson C., et al. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 93 7 (Jul 2008) 1101-1103
53. O'Sullivan S., Nat D., and Callon K. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signalling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 22 (2007) 1679-1689
54. Dewar A.L., Farrugia A.N., and Condina M.R. Imatinib as a potential antiresorptive therapy for bone disease. Blood 107 (2006) 4334-4337
55. El Hajj Dib I., Gallet M., Mentaverri R., et al. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol 551 (2006) 27-33
56. Cross T.J., Bagot C., Portmann B., et al. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 81 3 (Mar 2006) 189-192
57. Ridruejo E., Cacchione R., Villamil A.G., et al. Imatinib-induced fatal acute liver failure. World J Gastroenterol 13 48 (Dec 28 2007) pp. 6608-6611
58. Novartis Pharmaceuticals Corporation; Gleevec (imatinib mesylate): prescribing information (online). Available from:. http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf [accessed 22.05.09]
59. Novartis Pharmaceuticals Corporation; Tasigna (nilotinib): prescribing information (online). Available from:. http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf [accessed 22.05.09]
60. Bristol Myers Squibb Corporation; Sprycel (dasatinib): prescribing information (online). Available from:. http://packageinserts.bms.com/pi/pi_sprycel.pdf [accessed 22.05.09]
61. Ramanathan R.K., Egorin M.J., Takimoto C.H., et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26 4 (Feb 1 2008) 563-569
62. Gibbons J., Egorin M.J., Ramanathan R.K., et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26 4 (Feb 1 2008) 570-576
63. Gambacorti-Passerini C., le Coutre P., Zucchetti M., et al. Binding of imatinib by alpha(1)-acid glycoprotein. Blood 100 1 (2002 Jul 1) 367-368
64. O'Brien S.G., Meinhardt P., Bond E., et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 89 10 (Nov 17 2003) 1855-1859
65. Wang Y., Zhou L., Dutreix C., et al. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 65 6 (Jun 2008) 885-892
66. Hamada A., Miyano H., Watanabe H., et al. Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 307 2 (Nov 2003) 824-828
67. Kajita T., Higashi Y., Imamura M., et al. Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats. J Pharm Pharmacol 58 7 (Jul 2006) 997-1000
68. Rezai K., Lokiec F., Grandjean I., et al. Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide. BMC Pharmacol 7 (2007) 13
69. Breccia M., Muscaritoli M., Cannella L., et al. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res 32 10 (2008 Oct) 1626-1628
70. Kerkela R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12 8 (Aug 2006) 908-916
71. Atallah E., Durand J.B., Kantarjian H., et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110 4 (Aug 15 2007) 1233-1237
72. Atallah E., Kantarjian H., and Cortes J. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 13 1 (Jan 2007) 14 author reply 15-16
73. Hatfield A., Owen S., and Pilot P.R. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 13 1 (Jan 2007) 13 author reply 15-16
74. Verweij J., Casali P.G., Kotasek D., et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 43 6 (Apr 2007) 974-978
75. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia v.2.2009. Available from:. http://www.nccn.org [accessed 22.05.09]
76. Pye S.M., Cortes J., Ault P., et al. The effects of imatinib on pregnancy outcome. Blood 111 12 (Jun 15 2008) 5505-5508
77. Choudhary D.R., Mishra P., Kumar R., et al. Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol 17 1 (Jan 2006) 178-179
78. Ali R., Ozkalemkas F., Ozcelik T., et al. Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res 29 8 (Aug 2005) 971-973
79. AlKindi S., Dennison D., and Pathare A. Imatinib in pregnancy. Eur J Haematol 74 6 (Jun 2005) 535-537
80. Buyukbayrak E.E., Ergen B., Karsidag Y.K., et al. Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report. Arch Gynecol Obstet 278 2 (Aug 2008) 161-163
81. Garderet L., Santacruz R., Barbu V., et al. Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib. Haematologica 92 1 (Jan 2007) e9-10
82. Heartin E., Walkinshaw S., and Clark R.E. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. Leuk Lymphoma 45 6 (Jun 2004) 1307-1308
83. Prabhash K., Sastry P.S., Biswas G., et al. Pregnancy outcome of two patients treated with imatinib. Ann Oncol 16 12 (Dec 2005) 1983-1984
84. Russell M.A., Carpenter M.W., Akhtar M.S., et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 27 4 (Apr 2007) 241-243
85. Gambacorti-Passerini C., Tornaghi L., Marangon E., et al. Imatinib concentrations in human milk. Blood 109 (Feb 2007) 179
86. Cortes J., O'Brien S., Ault P., et al. Pregnancy outcomes among patients with chronic myeloid leukemia treated with Dasatinib. ASH Annual Meeting Proceedings. Blood 112 (2008) Abstract 32
87. He K., Lago M.W., Iyer R.A., et al. Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metab Dispos 36 12 (2008 Dec) 2564-2570
88. Cortes J., O'Brien S., and Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104 7 (Oct 1 2004) 2204-2205
89. Hensley M.L., and Ford J.M. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 40 2 Suppl. 2 (Apr 2003) 21-25
90. Ault P., Kantarjian H., O'Brien S., et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 24 7 (Mar 1 2006) 1204-1208